Tags

Type your tag names separated by a space and hit enter

An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques.
Nat Commun. 2020 08 21; 11(1):4207.NC

Abstract

The rapid spread of coronavirus SARS-CoV-2 greatly threatens global public health but no prophylactic vaccine is available. Here, we report the generation of a replication-incompetent recombinant serotype 5 adenovirus, Ad5-S-nb2, carrying a codon-optimized gene encoding Spike protein (S). In mice and rhesus macaques, intramuscular injection with Ad5-S-nb2 elicits systemic S-specific antibody and cell-mediated immune (CMI) responses. Intranasal inoculation elicits both systemic and pulmonary antibody responses but weaker CMI response. At 30 days after a single vaccination with Ad5-S-nb2 either intramuscularly or intranasally, macaques are protected against SARS-CoV-2 challenge. A subsequent challenge reveals that macaques vaccinated with a 10-fold lower vaccine dosage (1 × 1010 viral particles) are also protected, demonstrating the effectiveness of Ad5-S-nb2 and the possibility of offering more vaccine dosages within a shorter timeframe. Thus, Ad5-S-nb2 is a promising candidate vaccine and warrants further clinical evaluation.

Links

Publisher Full Text
ncbi.nlm.nih.gov
doi.org
PMC Free PDF

Authors+Show Affiliations

Feng L
Bioland Laboratory (GRMH-GDL), Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China. State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Wang Q
Bioland Laboratory (GRMH-GDL), Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China. University of Chinese Academy of Sciences, Beijing, China.
Shan C
State Key Laboratory of Virology, Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China.
Yang C
Guangzhou nBiomed Ltd, Guangzhou, China.
Feng Y
State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Wu J
State Key Laboratory of Virology, Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China.
Liu X
Guangzhou nBiomed Ltd, Guangzhou, China.
Zhou Y
Department of Forensic Medicine, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China.
Jiang R
State Key Laboratory of Virology, Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China.
Hu P
Bioland Laboratory (GRMH-GDL), Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
Liu X
Bioland Laboratory (GRMH-GDL), Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
Zhang F
Bioland Laboratory (GRMH-GDL), Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
Li P
Bioland Laboratory (GRMH-GDL), Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
Niu X
State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Liu Y
Bioland Laboratory (GRMH-GDL), Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
Zheng X
Bioland Laboratory (GRMH-GDL), Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
Luo J
Bioland Laboratory (GRMH-GDL), Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
Sun J
State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Gu Y
State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Liu B
Guangzhou nBiomed Ltd, Guangzhou, China.
Xu Y
Guangzhou nBiomed Ltd, Guangzhou, China.
Li C
State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Pan W
State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Zhao J
State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Ke C
Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, China.
Chen X
Bioland Laboratory (GRMH-GDL), Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
Xu T
Bioland Laboratory (GRMH-GDL), Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China.
Zhong N
State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Guan S
Guangzhou nBiomed Ltd, Guangzhou, China. guan_suhua@gznbio.com.
Yuan Z
State Key Laboratory of Virology, Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China. yzm@wh.iov.cn.
Chen L
Bioland Laboratory (GRMH-GDL), Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China. chen_ling@gibh.ac.cn. State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. chen_ling@gibh.ac.cn. Guangzhou nBiomed Ltd, Guangzhou, China. chen_ling@gibh.ac.cn.

MeSH

AdenoviridaeAnimalsAntibodies, NeutralizingAntibodies, ViralBetacoronavirusCOVID-19COVID-19 VaccinesCoronavirus InfectionsDose-Response Relationship, ImmunologicFemaleHEK293 CellsHumansImmunity, CellularMacaca mulattaMaleMiceMice, Inbred BALB CPandemicsPneumonia, ViralRespiratory SystemSARS-CoV-2Spike Glycoprotein, CoronavirusVaccines, SyntheticViral Vaccines

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

32826924

Citation

Feng, Liqiang, et al. "An Adenovirus-vectored COVID-19 Vaccine Confers Protection From SARS-COV-2 Challenge in Rhesus Macaques." Nature Communications, vol. 11, no. 1, 2020, p. 4207.
Feng L, Wang Q, Shan C, et al. An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques. Nat Commun. 2020;11(1):4207.
Feng, L., Wang, Q., Shan, C., Yang, C., Feng, Y., Wu, J., Liu, X., Zhou, Y., Jiang, R., Hu, P., Liu, X., Zhang, F., Li, P., Niu, X., Liu, Y., Zheng, X., Luo, J., Sun, J., Gu, Y., ... Chen, L. (2020). An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques. Nature Communications, 11(1), 4207. https://doi.org/10.1038/s41467-020-18077-5
Feng L, et al. An Adenovirus-vectored COVID-19 Vaccine Confers Protection From SARS-COV-2 Challenge in Rhesus Macaques. Nat Commun. 2020 08 21;11(1):4207. PubMed PMID: 32826924.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques. AU - Feng,Liqiang, AU - Wang,Qian, AU - Shan,Chao, AU - Yang,Chenchen, AU - Feng,Ying, AU - Wu,Jia, AU - Liu,Xiaolin, AU - Zhou,Yiwu, AU - Jiang,Rendi, AU - Hu,Peiyu, AU - Liu,Xinglong, AU - Zhang,Fan, AU - Li,Pingchao, AU - Niu,Xuefeng, AU - Liu,Yichu, AU - Zheng,Xuehua, AU - Luo,Jia, AU - Sun,Jing, AU - Gu,Yingying, AU - Liu,Bo, AU - Xu,Yongcun, AU - Li,Chufang, AU - Pan,Weiqi, AU - Zhao,Jincun, AU - Ke,Changwen, AU - Chen,Xinwen, AU - Xu,Tao, AU - Zhong,Nanshan, AU - Guan,Suhua, AU - Yuan,Zhiming, AU - Chen,Ling, Y1 - 2020/08/21/ PY - 2020/04/23/received PY - 2020/07/30/accepted PY - 2020/8/23/entrez PY - 2020/8/23/pubmed PY - 2020/9/15/medline SP - 4207 EP - 4207 JF - Nature communications JO - Nat Commun VL - 11 IS - 1 N2 - The rapid spread of coronavirus SARS-CoV-2 greatly threatens global public health but no prophylactic vaccine is available. Here, we report the generation of a replication-incompetent recombinant serotype 5 adenovirus, Ad5-S-nb2, carrying a codon-optimized gene encoding Spike protein (S). In mice and rhesus macaques, intramuscular injection with Ad5-S-nb2 elicits systemic S-specific antibody and cell-mediated immune (CMI) responses. Intranasal inoculation elicits both systemic and pulmonary antibody responses but weaker CMI response. At 30 days after a single vaccination with Ad5-S-nb2 either intramuscularly or intranasally, macaques are protected against SARS-CoV-2 challenge. A subsequent challenge reveals that macaques vaccinated with a 10-fold lower vaccine dosage (1 × 1010 viral particles) are also protected, demonstrating the effectiveness of Ad5-S-nb2 and the possibility of offering more vaccine dosages within a shorter timeframe. Thus, Ad5-S-nb2 is a promising candidate vaccine and warrants further clinical evaluation. SN - 2041-1723 UR - https://www.unboundmedicine.com/medline/citation/32826924/An_adenovirus_vectored_COVID_19_vaccine_confers_protection_from_SARS_COV_2_challenge_in_rhesus_macaques_ L2 - https://doi.org/10.1038/s41467-020-18077-5 DB - PRIME DP - Unbound Medicine ER -